The 3 most frequent any-grade TEAEs were diarrhea (66.5%), rash (65.8%) and hypertension (65.2%) in the gefitinib plus anlotinib group, and rash (52.9%), elevated alanine aminotransferase (ALT, 48.4%) and aspartate aminotransferase (AST, 48.4%) in the gefitinib plus placebo group. This evidence concerns the gene GPT and hypertensive disorder.